CN109069503A - 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用 - Google Patents

纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用 Download PDF

Info

Publication number
CN109069503A
CN109069503A CN201780024846.0A CN201780024846A CN109069503A CN 109069503 A CN109069503 A CN 109069503A CN 201780024846 A CN201780024846 A CN 201780024846A CN 109069503 A CN109069503 A CN 109069503A
Authority
CN
China
Prior art keywords
compound
nash
acid
group
nalmefene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780024846.0A
Other languages
English (en)
Chinese (zh)
Inventor
埃德温·Sc·吴
彼得·J·S·邱
许媺祺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiwanJ Pharmaceuticals Co Ltd
Original Assignee
TaiwanJ Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiwanJ Pharmaceuticals Co Ltd filed Critical TaiwanJ Pharmaceuticals Co Ltd
Priority to CN202311054107.XA priority Critical patent/CN117137917A/zh
Publication of CN109069503A publication Critical patent/CN109069503A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780024846.0A 2016-04-22 2017-04-20 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用 Pending CN109069503A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311054107.XA CN117137917A (zh) 2016-04-22 2017-04-20 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662326435P 2016-04-22 2016-04-22
US62/326,435 2016-04-22
US201662395436P 2016-09-16 2016-09-16
US62/395,436 2016-09-16
PCT/US2017/028529 WO2017184819A1 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311054107.XA Division CN117137917A (zh) 2016-04-22 2017-04-20 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用

Publications (1)

Publication Number Publication Date
CN109069503A true CN109069503A (zh) 2018-12-21

Family

ID=58668969

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780024846.0A Pending CN109069503A (zh) 2016-04-22 2017-04-20 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用
CN202311054107.XA Pending CN117137917A (zh) 2016-04-22 2017-04-20 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311054107.XA Pending CN117137917A (zh) 2016-04-22 2017-04-20 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用

Country Status (10)

Country Link
US (1) US10045977B2 (OSRAM)
EP (1) EP3445363A1 (OSRAM)
JP (1) JP2019514872A (OSRAM)
KR (1) KR20180129909A (OSRAM)
CN (2) CN109069503A (OSRAM)
AU (1) AU2017253228B2 (OSRAM)
BR (1) BR112018071705A2 (OSRAM)
CA (1) CA3021788C (OSRAM)
RU (1) RU2717677C1 (OSRAM)
WO (1) WO2017184819A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
US20190247373A1 (en) * 2016-07-14 2019-08-15 Children's Hospital Medical Center Methods for treating fibrosis
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CA3236690A1 (en) 2021-11-18 2023-05-25 Ju Hee Kim Sustained-release injectable composition containing naltrexone and method for preparing same
CN118234488A (zh) 2021-11-18 2024-06-21 创技公司株式会社 包含难溶性药物的微粒的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169508A1 (en) * 2003-05-16 2009-07-02 Jenkin Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
CN102048733A (zh) * 2010-12-23 2011-05-11 武汉同源药业有限公司 盐酸纳美芬的医药用途
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
AU2003234621A1 (en) 2002-05-17 2003-12-02 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
MY180160A (en) * 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169508A1 (en) * 2003-05-16 2009-07-02 Jenkin Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
CN102048733A (zh) * 2010-12-23 2011-05-11 武汉同源药业有限公司 盐酸纳美芬的医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A MOSLEHI 等: "Naltrexone attenuates endoplasmic reticulum stress induced hepatic injury in mice", 《ACTA PHYSIOLOGICA HUNGARICA》 *
GIOVANNI ADDOLORATO 等: "Management of Alcohol Dependence in Patients with Liver Disease", 《CNS DRUGS》 *

Also Published As

Publication number Publication date
BR112018071705A2 (pt) 2019-02-19
AU2017253228B2 (en) 2020-04-09
CN117137917A (zh) 2023-12-01
US20170304294A1 (en) 2017-10-26
RU2717677C1 (ru) 2020-03-25
CA3021788A1 (en) 2017-10-26
EP3445363A1 (en) 2019-02-27
AU2017253228A1 (en) 2018-09-27
AU2017253228A8 (en) 2019-01-17
KR20180129909A (ko) 2018-12-05
US10045977B2 (en) 2018-08-14
CA3021788C (en) 2021-08-03
WO2017184819A1 (en) 2017-10-26
JP2019514872A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
AU2017253228B2 (en) Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
JP2019514872A5 (OSRAM)
KR101868991B1 (ko) 피라졸 유도체 및 그 의약용도
CN102112134B (zh) 高脂血症，脂肪肝或肥胖的预防或治疗用组合物
CN103989668A (zh) 连翘苷元在制备预防或治疗肝损伤或肝衰竭药物中的应用
WO2016195355A1 (ko) 필버톤의 신규한 용도
KR20150130352A (ko) 지방간 질환을 치료하는 방법
WO2006034624A1 (fr) Procede pour la preparation d’une preparation de tetrodotoxine a base d’huile
CN100361649C (zh) 蜚蠊活成虫提取物的制备方法
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
CN103690535A (zh) 盐酸去亚甲基小檗碱在制备预防和/或治疗肝纤维化药物中的应用
CN110731964B (zh) 化合物as1842856的用途
WO2000078323A1 (fr) Utilisation de l'icariine dans la preparation de medicaments pour la prevention et le traitement de troubles de l'erection et de maladies vasoconstrictrices
CN112569237A (zh) 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用
TW201813646A (zh) 納美芬(nalmefene)在非酒精性脂肪肝炎(nash)的應用
US20140275138A1 (en) Method and products for treating diabetes
US20180318290A1 (en) Use of nalmefene in non-alcoholic steatohepatitis
CN118948846B (zh) 紫堇米定碱在制备治疗类风湿关节炎的药物中的用途
JPS62132822A (ja) 肝炎治療剤
CN103520183B (zh) Phyllanthoid A在制备降低血糖药物中的应用
CN110256453A (zh) 一种河豚毒素酯化物的制备方法
WO2019242764A1 (zh) 糖苷类化合物在制备防治糖尿病并发症的药物中的应用
CN112641779B (zh) Gw441756在制备预防和/或治疗脂肪肝药物中的应用
CN1647800A (zh) 一种河鲀油制剂及其制备方法
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181221

RJ01 Rejection of invention patent application after publication